We have previously shown that FGF23 acts as such an endocrine factor10, and here we describe that FGF23/FGFR4-mediated cardiac remodeling is reversible, suggesting its potential for serving as a cardio-protective drug target in CKD. Here, FGFR4 is linked to chronic kidney disease.